Lux Capital

🚨 Funding announcement! 🚨 Proud to co-lead Sakana AI's over $100M Series A with New Enterprise Associates (NEA) and Khosla Ventures! Sakana AI is pioneering nature-inspired AI, and we're excited to support their new collaboration with NVIDIA on AI research and infrastructure in Japan 🐟 🔗 https://lnkd.in/dPhFENRt

🚨 Funding announcement! 🚨 We're thrilled to lead eGenesis, Inc. $191M Series D round, accelerating their groundbreaking work in kidney transplants. A major step toward transforming organ transplantation! #biotech #xenotransplantation More here: https://lnkd.in/dU6QT-3E

Inspired by Lux Capital, EvolutionaryScale, and Enveda Biosciences's second annual Bio x ML Hackathon, powered by Amazon Web Services (AWS). Once again, this Hackathon will bring together the top minds in science and AI to advance human health, progress knowledge, and uncover solutions to challenging, unsolved problems in biology... Apply by Sept 22nd! https://hackathon.bio/ Thanks to: Tracie Rotter Eric Zimmerman Tess van Stekelenburg Matthew Nemeth #AWSstartups #innovation #advancinghumanhealth 🌿 ✨ 🚀

We're back! Lux Capital is running a Bio x ML Hackathon with EvolutionaryScale and Enveda Biosciences Bio from Oct 10-20! By bringing together the world’s top minds, we’re driving forward the next frontier of science with AI-driven tools and scientific imagination. Build on top of the latest foundation models like ESM3 (98B parameters, GPU access) and proprietary datasets to predict protein activity, model across therapeutic modalities, and develop next-gen biology applications. Model APIs, datasets & compute powered by Amazon Web Services (AWS), OpenAI, NVIDIA, DigitalOcean, EvolutionaryScale, Modal, LatchBio, Together AI, Enveda Biosciences, and RunPod. Open globally. Get started here: hackathon.bio

Why have algorithms not upended venture capital? Dario Soatto explains in his first column for the Riskgaming newsletter:

Co-founder and Managing Partner of Lux Capital Josh Wolfe is a master at understanding complex, emerging technologies. In our conversation, Josh shared how he identifies the next big thing, his contrarian views on nuclear energy, biotech, and robotics, as well as his thoughts on the state of the venture capital market today. Here are some key takeaways: → Obsessions Fuel Breakthroughs Josh often dives deep into a particular technology for many weeks, even years, juggling 10-12 of these obsessions at once. For example, his decade-long focus on using technology to replicate and understand smells seemed fruitless for years until the right technological breakthrough occurred. When you believe something is inevitable but aren’t sure of the timeline, continuing to pursue an idea can eventually lead to big rewards when timing and technology align. → How Josh Masters New Domains Josh dives deep into scientific research (not just page one) to quickly become knowledgeable in new fields, and he connects with top scientists to learn about breakthroughs before they’re public. By the time he talks to experts, he’s already well-informed, allowing him to spot trends early and make investment decisions off the beaten path. For example, when the venture world was fixated on solar, wind, and biofuels, Josh turned his attention to his well-informed thesis on nuclear energy. → De-Risking Investments to Maximize Returns Josh Wolfe emphasizes the importance of de-risking early investments by identifying key risks to the business and providing resources to mitigate them. Later investors will then be willing to pay a higher price because they face less uncertainty. His approach is not about being contrarian for its own sake, but about being ahead of the curve (much like moving to Brooklyn before it became mainstream). You want others to agree with you, just later. → Josh’s Harsh Take on the Future of VC Josh predicts that 30-50% of venture firms may not survive the next few years, particularly those that are unable to adapt to changing market dynamics. Josh believes the firms that will thrive are those that can be nimble, make smart capital allocations, and avoid the pitfalls that come from following the herd in overhyped sectors. More insights for anyone in tech or venture capital in the full episode: https://lnkd.in/dgxR4fMr

Lux MBA summer intern Bradley Aka shared his thoughts on digital twins and how they can be implemented to transform healthcare in his latest piece below. Check it out:https://lnkd.in/eazMG3nf

The latest edition of our Riskgaming newsletter arrives via Sri Lankan writer Yudhanjaya Wijeratne on why some regions have incredibly dynamic scientific and engineering innovation — and others don't.

A week after giving birth to my third child last September, I was preparing to take our first walk around the neighborhood, when I was hit with the worst headache of my life. Fifteen minutes later--and thanks to quick triage from Maven Clinic's Neel Shah, I found myself going over my will on the way to the hospital, where I would stay under intensive care and stroke and seizure watch for the next five days. Thank you to Emma Hinchliffe for sharing more about my harrowing experience with rare and often deadly postpartum preeclampsia in Fortune's Broadsheet today--and how it has re-invigorated my passion for women's health innovation and investment.

The future of the chip economy hinges on an extraordinary amount of manpower and brainpower required to design tomorrow's chips, and their rapidly spiraling costs. In this article, we explore how AI can change that: